Objective: In this study the effect of high dose octreotide LAR on glucose metabolism in patients with acromegaly was investigated. Design: A post-hoc analysis of a clinical trial enrolling 26 patients with acromegaly not controlled by standard maximal somatostatin analog (SSAs) dose and randomized to receive high-dose (60 mg/28 days) or high-frequency (30 mg/21 days) octreotide intramuscular injection (octreotide LAR) for 6 months. Methods: Glucose metabolic status was defined as worsened when a progression from normoglycemia to impaired fasting glucose (IFG) or from IFG to diabetes occurred or when an increase of HbA1c by at least 0.5% was demonstrated. An improvement of glucose metabolism was defined in the presence of a regression from IFG to normoglycemia and/or when HbA1c decreased by at least 0.5%. Results: Glucose metabolic status remained unchanged in the majority of patients (16/26 patients, 65.3%), worsened in six patients and improved in 4 patients. Pre-existing metabolic status did not predict worsening of glucose metabolism which, conversely, was significantly related to persistent biochemical activity of the disease. In fact, patients with worsened glucose metabolism exhibited a less frequent decrease in serum GH and IGF-I levels, compared with patients with improved or unchanged glucose metabolism (2/6 vs. 18/20; P = 0.01). Conclusion: An increase in octreotide LAR dose or frequency did not impact on glucose metabolism in most patients. Worsening of glucose metabolic status occurred in close relation with persistently uncontrolled acromegaly.

Effects of High-Dose Octreotide LAR on Glucose Metabolism in Patients With Acromegaly Inadequately Controlled by Conventional Somatostatin Analogue Therapy / G., Mazziotti; T., Porcelli; F., Bogazzi; G., Bugari; S., Cannavò; Colao, Annamaria; R., Cozzi; L., De Marinis; E., Degli Uberti; S., Grottoli; F., Minuto; M., Montini; M., Spinello; A., A. G. i. u. s. t. i. n.. - In: EUROPEAN JOURNAL OF ENDOCRINOLOGY. - ISSN 0804-4643. - ELETTRONICO. - Jan 6:(2011), pp. 140-145.

Effects of High-Dose Octreotide LAR on Glucose Metabolism in Patients With Acromegaly Inadequately Controlled by Conventional Somatostatin Analogue Therapy.

COLAO, ANNAMARIA;
2011

Abstract

Objective: In this study the effect of high dose octreotide LAR on glucose metabolism in patients with acromegaly was investigated. Design: A post-hoc analysis of a clinical trial enrolling 26 patients with acromegaly not controlled by standard maximal somatostatin analog (SSAs) dose and randomized to receive high-dose (60 mg/28 days) or high-frequency (30 mg/21 days) octreotide intramuscular injection (octreotide LAR) for 6 months. Methods: Glucose metabolic status was defined as worsened when a progression from normoglycemia to impaired fasting glucose (IFG) or from IFG to diabetes occurred or when an increase of HbA1c by at least 0.5% was demonstrated. An improvement of glucose metabolism was defined in the presence of a regression from IFG to normoglycemia and/or when HbA1c decreased by at least 0.5%. Results: Glucose metabolic status remained unchanged in the majority of patients (16/26 patients, 65.3%), worsened in six patients and improved in 4 patients. Pre-existing metabolic status did not predict worsening of glucose metabolism which, conversely, was significantly related to persistent biochemical activity of the disease. In fact, patients with worsened glucose metabolism exhibited a less frequent decrease in serum GH and IGF-I levels, compared with patients with improved or unchanged glucose metabolism (2/6 vs. 18/20; P = 0.01). Conclusion: An increase in octreotide LAR dose or frequency did not impact on glucose metabolism in most patients. Worsening of glucose metabolic status occurred in close relation with persistently uncontrolled acromegaly.
2011
Effects of High-Dose Octreotide LAR on Glucose Metabolism in Patients With Acromegaly Inadequately Controlled by Conventional Somatostatin Analogue Therapy / G., Mazziotti; T., Porcelli; F., Bogazzi; G., Bugari; S., Cannavò; Colao, Annamaria; R., Cozzi; L., De Marinis; E., Degli Uberti; S., Grottoli; F., Minuto; M., Montini; M., Spinello; A., A. G. i. u. s. t. i. n.. - In: EUROPEAN JOURNAL OF ENDOCRINOLOGY. - ISSN 0804-4643. - ELETTRONICO. - Jan 6:(2011), pp. 140-145.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/377404
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 42
  • ???jsp.display-item.citation.isi??? 41
social impact